Document Detail


Angiotensin II type 2 receptor in chronic kidney disease: the good side of angiotensin II?
MedLine Citation:
PMID:  19404281     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Angiotensin II is believed to mediate blood pressure-independent progressive renal damage in chronic kidney disease (CKD). The evidence is less definitive than has been implied, and the studies by Benndorf et al. suggest that angiotensin II acting through its type 2 receptor may even have beneficial effects, although the responsible mechanisms remain to be defined. These and other data suggest that the concept of blood pressure-independent angiotensin signaling being uniformly deleterious in CKD is an oversimplification that needs re-evaluation.
Authors:
Karen A Griffin; Anil K Bidani
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Kidney international     Volume:  75     ISSN:  1523-1755     ISO Abbreviation:  Kidney Int.     Publication Date:  2009 May 
Date Detail:
Created Date:  2009-04-30     Completed Date:  2009-07-07     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0323470     Medline TA:  Kidney Int     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1006-8     Citation Subset:  IM    
Affiliation:
Loyola University Medical Center and Hines Veterans Affairs Hospital, Department of Nephrology, Maywood, Illinois, USA. kgriffi @lumc.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angiotensin II / physiology*
Animals
Blood Pressure
Humans
Kidney Failure, Chronic / metabolism*
Receptor, Angiotensin, Type 2 / deficiency,  physiology*
Signal Transduction
Chemical
Reg. No./Substance:
0/Receptor, Angiotensin, Type 2; 11128-99-7/Angiotensin II

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Estimated glomerular filtration rate: time for a performance review?
Next Document:  Peripheral blood gene expression profiling in Sjögren's syndrome.